Cormorant Asset Management, LP's Form 4 filing
Corbus Pharmaceuticals Holdings, Inc. (CRBP) · filed Dec 15, 2025
- Accession no.
- 0000929638-25-004597
- Filed
- Dec 15, 2025, 4:18 PM ET
- Trade date
- Dec 11, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $344.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cormorant Asset Management, LPCIK 0001583977 | 10% Owner |
| Chen BihuaCIK 0001599214 | 10% Owner |
| Cormorant Global Healthcare Master Fund, LPCIK 0001618442 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Common Stock | SSaleDisposed | −30,029 | $11.46F1 | −$344,012.22 | 2,344,971 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price represents the weighted average sale price of Common Stock (the "shares") sold in a series of open market transactions on the transaction date at prices ranging from $11.20 to $12.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund.
Referenced by the price of 1 transaction in Table I.